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Abstract
Cisplatin and its platinum analogues, carboplatin and oxaliplatin, are some of the most widely 
used cancer chemotherapeutics. However, although cisplatin and carboplatin are primarily used in 
germ cell, breast and lung malignancies, oxaliplatin is instead used almost exclusively in 
colorectal and other gastrointestinal cancers. Here, we utilize a unique multi-platform genetic 
approach to study the mechanism of action of these clinically established platinum anti-cancer 
agents as well as more recently developed cisplatin analogues. We show that oxaliplatin, unlike 
cisplatin and carboplatin, does not kill cells via the DNA damage response. Rather, oxaliplatin 
kills cells by inducing ribosome biogenesis stress. This difference in drug mechanism explains the 
distinct clinical implementation of oxaliplatin relative to cisplatin and may enable mechanistically 
informed selection of distinct platinum drugs for distinct malignancies. These data highlight the 
functional diversity of core components of front line cancer therapy and the potential benefits of 
applying a mechanism-based rationale to the use of our current arsenal of anti-cancer drugs.
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The use of cisplatin in the clinic began over 45 years ago in the absence of understanding of 
the cellular and molecular mechanisms that underlie its efficacy1. Despite this, cisplatin has 
become a component of treatment regimens for at least 18 distinct tumor types2. However, 
cisplatin-induced side effects and the emergence of resistance to treatment led to the 
development of two derivatives, carboplatin and oxaliplatin, which have also seen 
considerable clinical use in a wide array of cancers. Interestingly, oxaliplatin has a different 
side effect profile than cisplatin and carboplatin, and it is used in colorectal and other 
gastrointestinal cancers where cisplatin and carboplatin have minimal efficacy. However, the 
decision to use oxaliplatin to treat colorectal cancer was primarily motivated by its activity 
against colorectal cancer cell lines in the human tumor cell line panel known as the NCI-60 
and not due to a rationale involving its mechanism of action3,4. Although the assumption has 
been that oxaliplatin, like cisplatin, kills cells by eliciting a DNA damage response, no 
satisfactory explanation for oxaliplatin’s unique clinical use and side effect profile has been 
identified. Here, we demonstrate that oxaliplatin acts through a fundamentally distinct 
mechanism of action relative to cisplatin and we propose that these agents should be used in 
a mechanism-targeted manner in the treatment of cancer.
Results
Diverse mechanisms of action for platinum compounds
To examine the mechanism of action of cisplatin and its platinum analogues we used an 
RNAi-based functional genetic strategy to predict mechanism of cytotoxic drug action5–7. 
This methodology has the advantages of being mammalian, isogenic and unbiased by dosage 
effects resulting from export or metabolism. Additionally, it has previously been used to 
characterize the mechanism of action of other metal based anti-cancer agents8–15. It is based 
on a fluorescence competition assay using lymphoma cells that are partially infected with 
eight short hairpin RNAs (shRNAs) that target distinct genes encoding proteins with known 
or putative roles in cell death signaling pathways: p53 (TP53), Chk2 (CHEK2), Chk1 
(CHEK1), ATR (ATR), ATX (SMG1), DNAPKcs (PRKDC), Bok (BOK) and Bim 
(BCL2L11). The shRNA-bearing cells either enrich or deplete relative to the uninfected 
population based on the survival advantage or disadvantage conferred by a given shRNA 
(Fig. 1a). The combined responses of these cells to different drugs constitute drug 
“signatures”. Signatures of all classes of clinically used cytotoxic agents have been 
generated and assembled into a reference set separated into eight distinct categories of drugs 
based on the constituents’ shared molecular mechanism of action (Supplementary Table S1). 
A new drug signature can then be classified by a probabilistic K-nearest neighbors algorithm 
to determine whether a new drug belongs to a class in the reference set or requires a new 
category not represented therein (Fig. 1b).
To eliminate dosage or potency effects from confounding the RNAi signatures, all agents 
were administered at a concentration that killed 80–90% (LD80–90) of the cells at 48 h. 
These LD80–90 concentrations varied greatly from one compound to the next 
(Supplementary Fig. 1a). However, via atomic absorption spectroscopy we determined that 
for cisplatin analogues representing low, medium and high potency, the amount of platinum 
required inside the cells for killing corresponded to their respective LD80–90 values 
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(Supplementary Fig. 1b). For instance, pyriplatin treatment at LD80–90 lead to much more 
intracellular platinum than the other LD80–90 treatment, indicating each molecule is 
relatively less toxic. Thus, differences in cellular uptake were effectively controlled using 
LD80–90 concentrations.
Next, to examine the mechanism of action of cisplatin, carboplatin and oxaliplatin we 
obtained their RNAi signatures. As expected, cisplatin and carboplatin were both predicted 
to be DNA cross-linkers (Fig. 1c,d, Supplementary Table S2, and Supplementary Fig. S2a). 
Previously, the three FDA-approved platinum based drugs had been understood to function 
primarily as DNA damaging agents that form intra- and interstrand cross-links. These cross-
links are, in turn, removed largely by excision repair, generating single or double-stranded 
breaks in the process16. However, despite the fact that oxaliplatin putatively forms 1,2-
intrastrand and other cross-links on DNA, oxaliplatin classified as being most similar to 
compounds that inhibit transcription or translation (Fig. 1c,d, Supplementary Table S2, and 
Supplementary Fig. S2a). These data may begin to explain why oxaliplatin has a different 
cytotoxicity profile and clinical application. Additionally, RNAi signatures of cisplatin and 
oxaliplatin taken in combination with 5-fluorouracil (5-FU), the primary drug with which 
oxaliplatin is paired with, preserved these mechanistic differences (Supplementary Fig. 3). 
Prior analysis of NCI-60 data similarly concluded that oxaliplatin acts distinctly relative to 
cisplatin and carboplatin, although no cellular function was identified as being responsible 
for the difference17. Notably, in this prior study, compounds clustered strictly by structure 
which is indicative of the NCI-60 methodology’s emphasis on drug metabolism and 
transport over mechanism of action18.
Interestingly, phenanthriplatin, a monofunctional and highly potent platinum(II) compound, 
also classified as a transcription/translation inhibitor (Fig. 1c,d, Supplementary Table S2, 
and Supplementary Fig. S2c). Because phenanthriplatin is incapable of making DNA cross-
links, yet also classifies as a transcription/translation inhibitor like oxaliplatin, it suggests 
that the ability of oxaliplatin to form cross-links on the DNA is irrelevant to its mechanism 
of action. We went on to characterize seven additional platinum compounds and discovered 
that most also classified as DNA cross-linkers or transcription/translation inhibitors 
(Supplementary Fig. S2b,c and Supplementary Table S2). Curiously, two monofunctional 
platinum agents, acriplatin and pyriplatin, were found to have mechanisms of action not 
represented in our reference set (Supplementary Fig. S2d and Supplementary Table S2). This 
suggests that potential mechanisms of action for platinum compounds extend beyond the 
scope of anti-cancer agents in current clinical use. Furthermore, these signature predictions 
are maintained in all permutations of leave-one-out cross-validation of the drugs in the 
reference set (Supplementary Table S3). Additionally, we used an indicator of structural 
similarity, the Tanimoto coefficient19, to hierarchically cluster the compounds and found that 
structural clustering was unable to recapitulate RNAi signature-based clustering, regardless 
of whether the compounds were clustered by their native structure or their anticipated 
structure once inside the cell (Supplementary Fig. S4). Thus, mechanism cannot be correctly 
predicted based on structure alone.
To more thoroughly examine the differences in RNAi signatures used to classify these 
molecules, we performed a detailed analysis of all of their signatures. The most notable 
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differences included decreased resistance with shChk2 and decreased sensitivity with 
shChk1 for the transcription/translation inhibitor-like compounds relative to the DNA cross-
linker-like compounds (Fig. 1e and Supplementary Table 4). As another means of 
visualizing the data, we utilized principal components analysis (PCA) to represent the 
variance of our data in fewer dimensions. Plotting all of our tested platinum analogues with 
canonical transcription/translation inhibitors, DNA cross-linking agents, and Top2 poisons, 
we saw that the transcription/translation inhibitors separated from DNA cross-linkers along 
the first principal component (PC1) (Fig. 1e). Upon examining the variable contributions 
that made up PC1, we saw that shChk2 contributed most strongly among the hairpins. We 
also identified Chk2 as the greatest contributor to the distinction between these two sets of 
drugs in a p185+ BCR-Abl p19arf−/− mouse model of acute lymphoblastic leukemia (ALL)20 
(Supplementary Fig. S2e,f).
DNA damage response affects response to cisplatin but not oxaliplatin
To confirm the RNAi signature data using a parallel approach, we examined drug response 
in the avian DT40 cell line21. Here, 40 different DT40 cell lines, each with a different gene 
knockout related to DNA damage repair and tolerance, were dosed with five different 
platinum agents. In agreement with our RNAi signatures, the DT40 knockouts showed 
distinct sensitivities to oxaliplatin and phenanthriplatin relative to the other three platinum 
agents (Fig. 2a,b, and Supplementary Tables S5–6). In particular, loss of genes involved in 
homologous recombination (HR) (XRCC2, XRCC3, BRCA2) and interstrand cross-link 
repair (ICR) (FANCC, FANCD2, FANCG) showed the greatest differences between the two 
categories of platinum agents. The relative lack of sensitivity of HR and ICR deficient cells 
to oxaliplatin suggests that it, like phenanthriplatin, fails to form intra- and interstrand cross-
links. Interestingly, genes necessary for replication bypass (POLZ and PCNA) were critical 
for all of the platinum derivatives. This result suggests that oxaliplatin and phenanthriplatin 
treatment create lesions on the DNA that are only toxic in the absence of normal replication 
bypass machinery. In addition, these results were recapitulated using RNAi against several 
genes related to DNA damage repair and/or tolerance in Eμ-Myc p19Arf−/− lymphoma cells 
and in Eμ-Myc p53−/− lymphoma cells (Supplementary Fig. S5a,b). Thus, relative drug 
sensitivities in the context of DT40 knockout cells support the RNAi-based category 
classifications.
Dependency on checkpoint kinases stratifies platinum agents
Given the importance of the two cell cycle checkpoint kinases, Chk1 and Chk2, in 
discriminating between the two mechanistic classes of platinum drug action and DNA 
damage response signaling, we decided to first confirm that these distinctions are relevant in 
vivo. To do this, we conducted a cell competition experiment using the Eμ-Myc p19Arf−/− 
lymphoma cells that were partially infected with GFP-tagged shChk2 and then tail-vein 
injected into syngeneic recipient mice. Tumors from untreated, cisplatin, oxaliplatin or 
phenanthriplatin treated mice were then analyzed for GFP percentage. As the in vitro data 
predicted, shChk2-containing cells significantly enriched compared to uninfected cells in 
mice treated with cisplatin but not in mice treated with oxaliplatin or phenanthriplatin (Fig. 
3a). These results suggest that dependence on Chk2 activity, a key mediator of the canonical 
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DNA damage response, represents a primary distinction between the mechanistic 
classifications of DNA cross-linkers and transcription/translation inhibitors.
Subsequently, we examined the cell cycle profiles of cells treated with phenanthriplatin, 
oxaliplatin, and cisplatin treatment for 12 h at LD80–90. Oxaliplatin and phenanthriplatin 
induced a G1 cell cycle arrest whereas cisplatin arrested cells in the S and G2/M phases 
(Fig. 3b). We obtained similar results with the three drugs after 24 h of treatment in human 
lung adenocarcinoma and colorectal cell lines, A549 and LoVo, respectively (Supplementary 
Fig. S6). To determine the mechanistic basis for these cell cycle differences, we examined 
signaling pathways that may be engaged following induction of the DNA damage response. 
As shown by western blot, p21 (CDKN1A) protein is activated more quickly in response to 
oxaliplatin and phenanthriplatin than cisplatin (Supplementary Fig. S7a). Additionally, 
knockdown of p21 sensitizes cells to oxaliplatin and phenanthriplatin treatment but elicits 
resistance to cisplatin (Supplementary Fig. S7b).
Next, to gain further insight into DNA damage signaling in response to these compounds, 
we examined the p53 activating kinase, Chk2. Chk2 is activated in response to double-strand 
breaks, whereby it goes on to phosphorylate p53 on serine 20 (serine 18 in mice), which 
relieves MDM2 inhibition of p5322. Thus, treatment of cells with DNA damaging agents 
selects for cells harboring Chk2 or p53 hairpins. Consequently, mechanistic characteristics 
of DNA cross-linking agents should be discernible by examining canonical markers of DNA 
damage. We therefore tested for γ-H2AX and phosphor-ser18 p53 by Western blot at 12 h 
with and without hairpins targeting Chk1 and Chk2 for cisplatin, oxaliplatin and 
phenanthriplatin. We observed that treatment with oxaliplatin and phenanthriplatin resulted 
in γ-H2AX signal, but this was not dependent on Chk2, as it was for cisplatin (Fig. 3c). All 
three drugs also elicited total p53 induction and phosphorylation of p53; however, this was 
dependent on Chk2 for cisplatin (Fig. 3d). Additionally, the same was observed for both γ-
H2AX and p53 at 4 h comparing cisplatin and phenanthriplatin with and without shChk2 
(Supplementary Fig. S8a,b). Moreover, we observed upregulation of p53 transcriptional 
targets Puma and Noxa following phenanthriplatin treatment, concomitant with the increase 
in p53 levels seen by western blot (Fig. 3e). Subsequently, we examined γ-H2AX and 
phospho-ser18 p53 at and prior to 4 h. Phenanthriplatin, and to a lesser degree oxaliplatin, 
induced γ-H2AX, phosphor-ser18 p53 and total p53 accumulation, sooner and to a greater 
degree than cisplatin (Supplementary Fig. S8c,d). Phenanthriplatin and oxaliplatin also 
caused more rapid cell death than cisplatin and doxorubicin (Supplementary Fig. S9). We 
confirmed that cisplatin-induced phosphorylation of serine 20 of p53 was Chk2 dependent in 
the human LoVo colorectal cell line (Supplementary Fig. S10a). Furthermore, the transcript 
levels of the pro-apoptotic gene, Noxa, were increased following treatment with all platinum 
agents tested in multiple human cell lines (Supplementary Fig. S10c–e). Taken together, the 
early activation of apoptosis along with the early appearance, persistence, and Chk2 
independence of γ-H2AX and phospho-ser18 p53 suggest a mechanism of cell death 
induced by oxaliplatin and phenanthriplatin that does not rely on canonical DNA strand-
break signaling.
Bruno et al. Page 5
Nat Med. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Oxaliplatin does not induce a DNA damage response
Considering the aforementioned rapid induction of γ-H2AX signal and early apoptosis 
following oxaliplatin and phenanthriplatin treatment, we examined γ-H2AX via 
immunofluorescence in order to distinguish DNA damage-related foci from pan-nuclear γ-
H2AX; the latter is indicative of apoptosis23,24. We observed, as expected, that cisplatin-
treated cells had γ-H2AX foci characteristic of a DNA damage response. However, similar 
to untreated cells, oxaliplatin and phenanthriplatin treated cells did not have γ-H2AX foci 
(Fig. 4a–d). Quantification of γ-H2AX signal showed that at both 4 and 8 h, nearly all of the 
γ-H2AX signal in oxaliplatin and phenanthriplatin-treated cells was derived from pan-
nuclear γ-H2AX (Fig. 4c). Additionally, in the human LoVo cell line we confirmed that 
oxaliplatin-treated cells had significantly fewer γ-H2AX foci compared to cisplatin-treated 
cells (Supplementary Fig. S10f).
To further explain the absence of a DNA damage response following treatment with 
oxaliplatin and phenanthriplatin, comet assays were performed 6 h after treatment. Comet 
assays test for the presence of smaller weight DNA fragments produced following DNA 
breaks. A neutral comet assay, most sensitive to DNA double-strand breaks, indicated that 
oxaliplatin and phenanthriplatin treatment results in significantly fewer double-strand breaks 
than untreated or cisplatin treated murine lymphoma or human breast cancer cells (Fig. 4e 
and Supplementary Fig. S10g). Interestingly, an alkaline comet assay, sensitive to both 
single and double-strand breaks, indicated that only oxaliplatin treatment yielded 
significantly fewer DNA breaks than either no treatment or cisplatin treatment (Fig. 4f). It 
has been previously shown that in the alkaline comet assay S-phase cells yield longer tails 
than G1 or G2 cells. This result is consistent with having a large proportion of cells in S-
phase as in the untreated condition, particularly relative to oxaliplatin and phenanthriplatin 
treatment25.
Oxaliplatin and phenanthriplatin induce ribosome biogenesis stress
Our RNAi signatures predicted the mechanism of action of oxaliplatin and phenanthriplatin 
to involve transcription or translation inhibition. To further explore this possibility, we first 
measured the amount of platinum on RNA and DNA after 3 h of cisplatin, oxaliplatin and 
phenanthriplatin treatment at LD80–90. Atomic absorption spectroscopy revealed that all 
three compounds were present at appreciable amounts on both nucleic acids (Fig. 5a). 
Interestingly, oxaliplatin treatment yielded the least amount of platinum on either nucleic 
acid - potentially because it has the lowest LD80–90 concentration.
Defects in ribosome biogenesis can rapidly induce cell death in a p53-dependent and DNA 
damage-independent manner26. Given the similarity between this type of cell death and that 
induced by oxaliplatin and phenanthriplatin treatment, we examined ribosomal RNA (rRNA) 
synthesis following drug treatment. Indeed, we observed that within 30 minutes, pre-rRNA 
was decreased by nearly 50% in response to oxaliplatin and phenanthriplatin treatment (Fig. 
5b). At later time points, pre-rRNA was upregulated many-fold by oxaliplatin and 
phenanthriplatin exposure – a phenotype paralleled by actinomycin D, a known inducer of 
ribosome biogenesis stress26, but not cisplatin (Fig. 5b). Importantly, RNA polymerase II 
transcript levels were unaffected by treatment with any of the platinum agents 
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(Supplementary Fig. S11). Finally, to demonstrate on a functional genetic level that 
ribosome biogenesis stress was relevant to cell death caused by oxaliplatin and 
phenanthriplatin, we examined the role of RPL11 (RPL11) in drug-induced cell death. 
Ribosome biogenesis stress results in excess subunits of RPL11 that then bind Mdm2 and 
block the ability of Mdm2 to bind p5326. shRNA-mediated knockdown of RPL11 in Eu-Myc 
p19Arf−/− lymphoma cells and A549 human lung adenocarcinoma cells confers resistance to 
agents that induce ribosome biogenesis stress, including actinomycin D, rapamycin, 
mithramycin A, BMH-21 and 5-FU (Fig. 5c and Supplementary Fig. S12a–c). shRPl11 also 
induced resistance to oxaliplatin or phenanthriplatin treatment. Furthermore, we examined 
total p53 and cleaved Poly-ADP ribose polymerase 1 (cPARP) levels with or without an 
RPL11 hairpin 12 h after treating with the platinum agents and actinomycin D (Fig. 5d and 
Supplementary Fig. S12d). We saw that RPL11 knockdown led to diminished total p53 and 
cleaved PARP1 levels in cells treated with actinomycin D, oxaliplatin or phenanthriplatin, 
but not cisplatin. This effect is particularly strong when accounting for p53 and cPARP 
induction caused by knockdown of an essential component of the ribosome such as RPL11. 
Thus, the ribosome biogenesis stress pathway is a central mediator of oxaliplatin and 
phenanthriplatin cytotoxicity.
The localization of nucleolar proteins is altered in a characteristic manner in response to 
different types of cellular stress27, including impaired translation. After 8 h of treatment Eu-
Myc p19Arf−/− lymphoma cells with the platinum agents and actinomycin D, we observed 
differences in the localization of nucleophosmin and fibrillarin, two proteins normally 
localized to the nucleolus (Supplementary Fig. S13a). Cisplatin treatment did not result in 
any cells with nucleolar foci whereas actinomycin D, oxaliplatin and phenanthriplatin 
treatment resulted in a modest increase relative to no treatment (Supplementary Fig. S13b). 
More notably, nucleophosmin was predominantly found outside the nucleus for roughly 80 
percent of cisplatin treated cells, but not in the other conditions (Supplementary Fig. S13c). 
The unique localization of nucleolar proteins among platinum agents further indicates that 
oxaliplatin and phenanthriplatin have a mechanism of action that is distinct from cisplatin 
and more similar to actinomycin D.
Next we sought to gain more insight into the influence oxaliplatin may exert on translation 
machinery. To do so, we first examined the polysome profiles of Eu-Myc p19Arf−/− 
lymphoma cells after 6 h of treatment with cisplatin, oxaliplatin and phenanthriplatin. Cells 
treated with oxaliplatin or phenanthriplatin had significantly fewer polysomes relative to 
monosomes compared to untreated or cisplatin treated cells (Fig. 5e,f and Supplementary 
Fig. S14). Thus, the global translation machinery is significantly perturbed by oxaliplatin 
treatment. Next, to more directly demonstrate the potential disruptive effect oxaliplatin 
treatment had on translation, we quantified nascent protein synthesis via a click-chemistry 
compatible puromycin analogue28. Indeed, we observed in multiple cancer cell lines that 
oxaliplatin disrupts protein synthesis as early as 9 h after treatment (Fig. 5g and 
Supplementary Fig. S15).
If oxaliplatin impairs ribosomal function, we would expect to see an effect of oxaliplatin 
treatment on the efficacy of known translation inhibitors. To examine this possibility, we 
treated cells with a combination of rapamycin, an mTOR inhibitor and known ribosome 
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biogenesis stress inducer, and either cisplatin or oxaliplatin. We then measured synergy or 
antagonism by comparing to the Bliss Independence additivity model29. We saw that the 
combination of cisplatin and rapamycin was additive, as indicated by the near zero deviation 
from Bliss Independence (Fig. 5h). However, the combination of oxaliplatin and rapamycin 
was very antagonistic. Interestingly, this antagonism was not present if oxaliplatin was dosed 
before rapamycin, indicating an epistatic relationship between the mechanisms of action of 
the two drugs (Fig. 5i). To further study this relationship, we examined RNAi signatures to 
understand how the mechanisms of action varied in combination. Interestingly, the signature 
was more similar to rapamycin alone than oxaliplatin alone whether dosed simultaneously or 
dosed with oxaliplatin 6 h prior to rapamycin (Fig. 5j). This suggests that active translation 
must be occurring in order for oxaliplatin to exert its cytotoxic effects.
Ribosome biogenesis stress sensitizes cells to oxaliplatin
Next, we sought to determine if ribosome biogenesis stress was a central determinant of 
oxaliplatin efficacy in human cells and across diverse tumor types. To perform this analysis, 
we utilized the NCI-60 human cancer cell line database, which includes gene expression 
data for each cell line and their oxaliplatin treatment response. Using the CellMiner NCI-60 
database query tool30, we were able to probe for genes whose expression in naïve cells 
correlated to sensitivity to oxaliplatin treatment. For example, RSL24D1, the gene most 
highly correlated to sensitivity is shown in comparison to drug response profile of 
oxaliplatin (Fig. 6a and Supplementary Fig. S16). By performing gene ontology annotation 
via DAVID on the list of 417 genes whose expression significantly correlated with 
oxaliplatin sensitivity, we identified an enrichment of terms related to translation, the 
ribosome and rRNA (Fig. 6b)31,32. Additionally, Gene Set Enrichment Analysis (GSEA) on 
the same set of genes identified “ribosome” as the only significantly enriched KEGG 
pathway (Fig. 6c)33. Performing similar analysis for cisplatin at the same threshold used for 
oxaliplatin only yielded one gene, SFLN11. Whereas the previous analysis examined gene 
expression relative to the entire set of cell lines, we wanted to see if expression of translation 
machinery correlated with oxaliplatin sensitivity within particular cancer types. Indeed, we 
saw that in both lung and breast cancer cell lines, higher translation machinery expression 
correlated with an increase in oxaliplatin sensitivity (Fig. 6d).
We reasoned that this increased expression of translation machinery represents a “translation 
addiction” and that ribosome biogenesis stress inducers kill by depriving the cell of 
translation machinery. Thus, a further increase of translation machinery expression would 
buffer against translation machinery depriving treatments such as ribosome biogenesis stress 
inducers. To examine this, we knocked down PTEN (PTEN) in order to upregulate the 
mTOR pathway and thus elevate translation machinery expression (Supplementary Fig. 
S17). Indeed, upon knocking down PTEN, the cells were rendered more resistant to known 
ribosome biogenesis stress inducers actinomycin D and 5-FU, as well as to oxaliplatin (Fig. 
6e). Interestingly, we also saw that PTEN knockdown sensitized to cisplatin.
We next wanted to explore how these results might be relevant to the clinic. Given the 
frequent use of oxaliplatin in the treatment of colorectal cancer, we examined whether 
translation addiction could underlie oxaliplatin efficacy in this disease as opposed to cancers 
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where oxaliplatin shows little efficacy. We compared gene expression between all available 
colorectal and ovarian tumor samples from the The Cancer Genome Atlas (TCGA)34,35. We 
then performed GSEA on all differentially expressed genes between the two cancer types. 
Based on genes that are upregulated in colorectal cancer relative to ovarian cancer, GSEA 
identified the “ribosome” as one of the most enriched pathways that distinguishes colorectal 
cancer from ovarian cancer (Fig. 6f and Supplementary Table S7). GSEA did not identify 
any significant pathway enrichment from genes upregulated in ovarian cancer relative to 
colorectal cancer (Supplementary Table S8). Collectively, these data argue that the efficacy 
and clinical utility of oxaliplatin is derived from its ability to induce ribosome biogenesis 
stress.
Finally, we wanted to determine if we could identify correlates of oxaliplatin response in 
cancers that are not typically thought to respond to oxaliplatin. Prior studies have indicated 
that APC (APC), a key negative regulator of the Wnt pathway, loss in colorectal cancer 
causes a “translation addiction” that is necessary for tumorigenesis36. Thus, we examined 
Wnt pathway genes and their correlation to translation metagene expression in the TCGA 
expression databases37. Interestingly, we found that APC expression significantly correlated 
with translation metagene expression in several cancers, including breast and lung (Fig. 6g 
and Supplementary Fig. S18). We chose breast cancer for further examination as the NCI-60 
breast cancer cell lines had the best correlation between translation machinery expression 
and oxaliplatin sensitivity. Using a panel of breast cancer cell lines, we confirmed that APC 
expression correlated with oxaliplatin sensitivity (Fig 6h). Therefore, APC expression may 
represent a marker of oxaliplatin sensitivity in breast cancers, and potentially other cancers 
as well.
Discussion
Our findings have significant implications for the evaluation of small molecules and their 
derivatives used in the clinic. First, in addition to potential changes in drug 
pharmacodynamics and pharmacokinetics, alterations in the nature of the ligands in 
platinum complexes have profound implications for primary mechanism of action. Thus, 
platinum drugs may not function interchangeably with their derivatives in cancer regimens. 
This phenomenon explains a lack of efficacy for oxaliplatin in the treatment of malignancies 
conventionally treated by cisplatin, as well as the unanticipated and poorly understood value 
of oxaliplatin as a treatment for colorectal cancer38–41. Second, changes in small molecule 
structure can alter the molecular determinants of chemotherapeutic response. For example, 
instead of cisplatin, oxaliplatin has been tested as a front-line treatment for breast and non-
small-cell lung cancer (NSCLC)42–47. Furthermore, recent sequencing data has shown that 
greater than ten percent of breast and non-small cell lung cancers harbor inactivating 
mutations in ATM and Chk248,49. Our data suggest that these mutant tumors may have 
differential responses to cisplatin versus oxaliplatin. Thus, tumor mutations may represent 
important determinants of susceptibility to related platinum drugs.
Additionally, our data suggest that a “translation addiction” in colorectal cancer is 
responsible for the effectiveness of oxaliplatin. Notably, other studies have indirectly 
associated the translation machinery with the mechanism of oxaliplatin-mediated cell 
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killing. In one study, three oxaliplatin resistant sublines were generated and microarrays 
were performed to compare the resistant and parental cell lines50. In each pair of cell lines, a 
significant portion of the differentially expressed transcripts between the resistant and 
parental lines corresponded to genes composing the ribosome. Another study generated an 
oxaliplatin sensitivity predictor based on NCI-60 oxaliplatin dose responses and cell line 
gene expression data51, which enabled prediction of the responses to oxaliplatin in both cell 
lines in vitro as well as with patient colorectal cancer xenografts. Additionally, others used 
microarray technology to build gene expression signatures to that best predicted outcomes in 
clinical colorectal cancer cases. Despite this unbiased approach their signatures consisted of 
ribosome components52–57. Despite the implications for a role of the translation machinery 
in colorectal cancer, none of the aforementioned studies made such a connection.
mTOR-dependent translation elongation plays a critical role in colorectal cancer 
tumorigenesis36. For example, APC-deficient lesions increase protein synthesis, such that 
the progression of tumorigenesis is prevented by rapamycin. Thus, “translation addiction” 
accompanies colorectal cancer progression, making rapamycin an attractive therapeutic 
option. Additionally, our data indicate that APC and the translation machinery are linked in 
other cancer types. However, despite numerous attempts, rapamycin has not attained a solid 
foothold in cancer treatment, owing in part to cell intrinsic resistance mechanisms such as 
compensatory upregulation of PI3K signaling58 and the development of rapamycin 
insensitive mTOR mutations59. In cancer types for which rapamycin has failed in clinical 
trials, oxaliplatin may be viewed as a preferable choice for inhibition of translation. 
Moreover, given the role of tumor-intrinsic Wnt signaling in suppressing anti-tumor T-cell 
immune responses60, therapies like oxaliplatin that are more effective in Wnt activated 
tumors present a potential alternative to immunotherapy.
Although previous studies have identified differences in cellular response between cisplatin 
and oxaliplatin, ours is the first to identify causal links between oxaliplatin, ribosome 
biogenesis stress and cell death. For instance, oxaliplatin creates fewer cross-links per base 
than cisplatin, yet retains its cytotoxicity61. We suggest that the ability of oxaliplatin to 
cross-link DNA may be of questionable relevance, for we do not see activation of the DNA 
damage response. However, oxaliplatin-modified DNA could still lead to inhibition of rRNA 
synthesis, which would ultimately be responsible for ribosome biogenesis stress. In addition, 
one can envision scenarios in which oxaliplatin-modified rRNA, mRNA and/or protein could 
all potentially contribute to ribosome biogenesis stress. A DNA damage response-
independent mechanism of cell death is consistent with previous observations that cisplatin- 
or oxaliplatin-resistant cell lines often do not exhibit cross-resistance3. Finally, an analysis 
of the effects of various chemotherapeutics at a range of concentrations on rRNA synthesis 
and processing found that at high enough concentrations of many agents, including cisplatin 
and oxaliplatin, perturb this process62. However, this study did not ascribe a causal link 
between ribosome biogenesis perturbation and cell death. Thus, although many 
chemotherapeutics may inhibit ribosome biogenesis at high drug concentrations, this 
behavior is unlikely to be their primary mechanism of action. Our findings demonstrate that 
at clinically relevant, and lower, concentrations oxaliplatin causes ribosome biogenesis stress 
whereas cisplatin does not. Thus, our work demonstrates that perturbation of ribosome 
biogenesis is functionally important for oxaliplatin, and not cisplatin, to mediate cell death.
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Online Methods
shRNA Constructs
All shRNAs used were in the MLS retroviral vector with the exception of RPL11 in 
TMPVIR63,64. Transfection and infection were performed as previously described6. Unless 
shown, all knockdowns were previously validated for knockdown and off-target effects5. 
shRNA target sequences listed in Supplementary Table S9.
GFP Competition Assays
Eμ-Mycp19arf−/−, Eμ-Mycp53−/− lymphoma or p185+ BCR-Ablp19arf−/− leukemia cells were 
infected with GFP-tagged shRNAs such that 15–25% of the population were GFP positive. 
An eighth of a million cells in 250μL B-cell media (BCM) were then seeded into 24-well 
plates. For wells that would remain untreated as a control, only 1/16th of a million cells were 
seeded. Next, 250μL of drug containing media was added to the cells. After 24 h, 300μL of 
cells from untreated wells are removed and replaced by 300μL fresh BCM. All wells then 
received 500μL BCM before being placed in the incubator for another 24 hours. At 48 h, 
cells transduced with the control vector, MLS, were checked for viability via flow cytometry 
on a BD FACScan using propidium iodide (PI) as a live/dead marker. Untreated wells then 
had 700μL of cells removed and replaced with 700μL fresh media followed by a further 1mL 
of fresh media. Wells for which drug had killed 80–90% of cells (LD80–90) were then 
diluted further by adding 1mL of BCM. Finally, at 72 h all wells for which an LD80–90 was 
achieved, as well as the untreated samples, were run via flow cytometry to determine GFP%. 
For shRPL11 experiments the above procedures were followed except in the presence of 
1μg/mL doxycycline, including 24 h of pre-incubation of the hairpin containing cells in 
doxycycline. For all competition assays, at least three separate biological replicates were 
performed. Here, we define biological replicates as a fresh thaw that was infected, selected 
or sorted if necessary, then run through the comeptition assay.
RNAi Signatures
Drugs were dosed to achieve an LD80–90 in Eμ-Myc p19arf−/− cells by propidium iodide 
exclusion as determined by flow cytometry at 48 h. GFP enrichment/depletion was then 
determined by flow cytometry at 72 h. Linkage ratios and p-values were generated as 
described previously5–7. All flow cytometry was conducted using a BD FACScan. For all 
RNA signatures, at least three separate biological replicates were performed. Here, we 
define biological replicates as a fresh thaw of Eμ-Myc p19arf−/− cells that were infected, 
selected or sorted if necessary, then run through the signature assay.
Code Availability
Parameters and code for the modified K nearest neighbors (K-NN) algorithm for 
determining drug mechanism of action can be found in previous publications5,7.
Drug Doses
Unless otherwise noted, all drugs were administered to Eμ-Mycp19arf−/−, Eμ-Mycp53−/− 
lymphoma or p185+ BCR-Ablp19arf−/− leukemia cells at a concentration to achieve an 
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LD80–90 and 48 h as assessed via flow cytometry on a BD FACScan using propidium 
iodide as a live/dead marker. For time-point experiments, a portion of each sample was 
cultured until 48 h post-treatment to assure LD80–90 was achieved. If not, that sample was 
discarded and not included in further analysis. Similarly rigorous equipotent dosing was 
followed for adherent cell lines by first dosing over a large concentration range for 96 h and 
analyzing cell number via CellTiter-Glo (Promega). Then, for future equipotent doses only 
concentrations that achieved an IC80 at 96 h were used. For area under the curve 
calculations, whole dose response curves were analyzed with at 96 h and analyzed via 
MatLab 2015a (MathWorks). All drug doses were performed in at least once from three 
independent cultures.
Cell Cycle
One to two million cells were collected per sample after treatment with a concentration of 
drug required to achieve an LD80–90 at 48 h for Eμ-Mycp19arf−/− or IC80 at 96 h for A549 
and LoVo. They were washed in PBS and then resuspended in 1mL of PBS+2% fetal bovine 
serum (FBS). Cells were then fixed in 70% ethanol overnight at -20° C. Cells were then 
rehydrated with 5mL of PBS, spun out of ethanol and then washed in PBS. Next, 1mL of PI 
staining solution (3.8mM sodium citrate, 50μg/mL PI in PBS) and 20 μL of RNAse A were 
used to resuspend the pellet. Cells were then incubated overnight at 4°C before FACS on a 
BD FACScan. Cell cycle profiles were analyzed using FlowJo V10.
RNA Isolation and Expression Analysis
Total RNA was isolated via QIAshredder and Qiagen RNeasy Mini Kit and cDNA was 
generated via M-MLV Reverse Transcriptase with RNaseOUT (ThermoFisher Scientific) 
and random hexamers. qRT-PCR was performed with Fast SYBER Green Mastermix and 
StepOnePlus Real-Time PCR System (Applied Biosystems) with three biological replicates, 
each with two technical replicates. Primer sequences listed in Supplementary Table S10.
Western Blotting
Cell pellets were washed in PBS and frozen before being lysed in RIPA buffer. They were 
then boiled after the addition of Laemmli sample buffer and run on an SDS-PAGE gel. From 
the gel they were transferred to Millipore immobilin-P membranes. The antibodies used 
were mouse anti-p53 (NCL-p53–505, Novocastra; 1:500), human anti-p53 (2524, Cell 
Signaling; 1:1,000), anti-phospho p53 (Ser 15) (9284, Cell Signaling; 1:1,000), anti-phospho 
p53 (Ser 20) (9287, Cell Signaling; 1:1,000), anti-γ-H2AX (20E3, Cell Signaling; 1:1,000), 
anti-p21 (sc-6246, Santa Cruz, 1:200), anti-cPARP1 (9544, Cell Signaling, 1:1,000), anti-
GAPDH (sc-32233, Santa Cruz, 1:200), anti-β-actin (13E5, Cell Signaling; 1:1,000), anti-
HSP90 (68/Hsp90, Becton Dickinson; 1:6,000).
Cell Culture
Eμ-Myc p19arf−/−, Eμ-Myc p53−/− and p185+ BCR-Abl p19arf−/− primary murine tumor 
cells were cultured according to established protocols65. DT40 cells were cultured at 37°C 
with 5% CO2 in RPMI-1640 medium with glutamine (11875, Invitrogen, Carlsbad, CA) 
supplemented with 1% chicken serum (16110-082, Invitrogen, Carlsbad, CA), 10-5 M β-
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mercaptoethanol (M-3148, Sigma-Aldrich, St. Louis, MO), penicillin-streptomycin 
(15140-122, Invitrogen), and 10% FBS (100-106, Gemini Bio-Products, West Sacramento, 
CA). A549, SW480, LoVo, CAMA-1, Hs578T, ZR-75-1, BT549, SK-BR-3 and HCC1937 
cells were obtained from ATCC (CCL-185, CCL-228, CCL-229, HTB-21, HTB-126, 
CRL-1500, HTB-122, HTB-30 and CRL-2336) and cultured according to ATCC guidelines. 
All cell lines, except those obtained and used directly from ATCC, were tested for 
mycoplasma and found to be negative (MycoAlert, Lonza). No authentication was 
performed.
Cellular Uptake of Platinum
Two million Eμ-Myc p19arf−/− cells were dosed at concentrations required to achieve an 
LD80–90 at 48 h or at 5μM in three biological replicates. After 3 h, they were washed three 
times in PBS, pelleted and frozen. Atomic absorption spectroscopic analysis was then 
performed as previously described66.
Structure-based Hierarchical Clustering
The ChemmineR R package was used to calculate Tanimoto coefficients and perform 
hierarchical clustering.
DT40 Knockout Line Drug Sensitivity Analysis
To measure the sensitivity, cells were continuously exposed to various concentrations of 
drugs for 72 h in triplicate. Cell survival was determined using the ATPlite 1-step kit 
(PerkinElmer) and an EnVision 2104 Multilabel Reader. To evaluate the relative cellular 
sensitivity of each mutant to wild type cells, logarithm sensitivity curves were used to 
determine the concentration that causes 90% reduction of ATP activity (IC90). The IC90 
value of each mutant was divided by that of wild type cells on the same plate. Finally, the 
quotient was converted to a logarithmic scale (base 2). Pairwise distances were calculated 
via the ‘pdist’ function with the Euclidian distance metric in Matlab 2013b.
Immunofluorescence Staining
Eμ-Myc p19arf−/− cells were dosed at an LD80–90 and after 4 or 8 h of treatment placed on 
slides via cytospin. LoVo cells were dosed at IC80 and fixed after 12 h or treatment. Cells 
were then dried and stained with anti-γ-H2AX (20E3, Cell Signaling; 1:500) and DAPI or 
anti-NPM (B0556, Sigma, 1:2000), anti-Fibrillarin (ab5821, Abcam, 1:500) and DAPI. Alex 
Fluor 488 or 555 was used as a secondary and then samples were mounted with Prolong 
Gold. An EVOS FL Auto microscope was used for imaging. Image analysis was performed 
using CellProfiler on the original images.
Comet Assays
Eμ-Myc p19arf−/− cells were dosed at an LD80–90 and after 6 h were washed and prepared 
for either alkaline or neutral comet assays. Comet tail analysis was performed using 
CaspLab using images that were all equally level adjusted in Adobe Photoshop. ZR-75-1 
cells were dosed at an IC80 and after 24 h were washed and prepared for neutral comet 
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assays. CellProfiler was used to analyze ZR-75-1 comets. The Trevigen CometAssay Kit 
was used for both cell lines.
In vivo Competition Assay
Two million Eμ-Myc p19arf−/− cells were partially infected with shChk2 and tail vein 
injected into 8-week old female C57BL/6 mice. Cisplatin, oxaliplatin or phenanthriplatin in 
sterile saline were administered via intraperitoneal injection at disease presentation (7mg/kg, 
5mg/kg or 3mg/kg, respectively) and mice were sacrificed and tumors harvested upon 
relapse, 2–3 days after treatment. Disease presentation and relapse were defined as the 
presence of palpable lymph node burden. Fold change in GFP% was assessed relative to 
untreated mice after tumor cell harvesting by flow cytometry on a BD FACScan. Each 
treatment group had five or six mice. This was chosen independently of statistical power 
analysis. No randomization or blinding methods were used to determine treatment branches. 
The experiment was performed in accordance to MIT’s Committee on Animal Care (CAC) 
prior to execution.
Combination Doses and Bliss Independence
Eμ-Mycp19arf−/− lymphoma cells were treated with drug and analyzed as detailed above, 
except with two drugs in combination in a 3×5 dose response matrix where the outer wells 
were only exposed to a single drug6. The single drug wells were then used to calculate the 
expected Bliss Independence values of the combination wells. The expected Bliss 
Independence values were then subtracted from the observed values. The minimum or 
maximum value in the matrix was then chosen as the minimum or maximum percent excess 
under Bliss Independence.
Statistical Analysis
Two-sided, non-parametric tests were performed unless otherwise specified. If two 
conditions were compared, Mann-Whitney U-test was used. If more than one condition was 
compared to a control condition then one-way ANOVA with Dunnett’s Multiple Comparison 
Test was used. If a t-test was used, the data were first confirmed to fit a normal distribution 
via the ‘kstest’ function in Matlab 2015a. See figure legends for details on type of replicate 
and n values used.
Principal Component Analysis
Principal component analysis (PCA) was used to provide another means of visualizing our 
data, and was not used to classify new compounds. This was done via Matlab 2015a. The 
‘pca’ function was used with data from Supplementary Table S4 to generate the necessary 
input variables for the ‘biplot’ function.
Bioinformatic Analysis
CellMiner was used to obtain NCI-60 oxaliplatin sensitivity-expression level correlation 
values30. Benjamini-Hochberg correction was then used to eliminate genes above an FDR 
threshold of 0.05. For the TCGA tumor expression analysis, RNA-seq gene-level raw count 
data for colorectal and ovarian cancer tumor samples that went through the same pipeline for 
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generation of expression levels (RPKM values)(193 and 420 samples respectively) were 
downloaded from the TCGA data portal. The Bioconductor edgeR package in R was used to 
perform normalization and analysis for differential expression between these two cancer 
types67. We obtained 3247 significantly differentially expressed genes between these two 
cancer types, with a log2-fold change in normalized tag counts greater than 2.5 
(corresponding to a Benjamini-Hochberg corrected p-value of 5.8E-3 from a negative 
binomial generalized linear model fit). Among these genes, 1909 and 1338 were 
significantly up-regulated and down-regulated, respectively, in ovarian cancer compared to 
colorectal cancer. Significantly correlated (NCI-60) or differentially expressed (TCGA) 
genes were then loaded in Gene Set Enrichment Analysis and the pre-ranked list tool was 
used33.
For both NCI-60 and TCGA datasets a translation metagene was obtained by averaging 
expression of 120 genes known to be involved in translation for each. To demonstrate 
correlation between oxaliplatin sensitivity and translation, we plotted the GI50 values (log-
scale) against the metagene expression levels for lung and breast cancer cell lines in the 
NCI-60 catalogue. To examine associations between Wnt pathway activity and expression 
levels of the translation machinery, we calculated Pearson correlation coefficients of the 
translation metagene expression with that of known Wnt pathway genes in the Reactome 
database for breast cancer samples in the TCGA database. A heatmap of expression values 
of translation machinery genes ordered by decreasing APC expression values was then 
plotted to visualize such correlations.
Ribosome Profiling
One million cells for each of three replicates were harvested by centrifugation at 300g for 5 
m, resuspended in ice-cold PBS containing 100μg/mL cycloheximide and centrifuged again. 
Cell pellets were flash frozen in liquid nitrogen. To prepare the lysate, cell pellets were 
thawed in lysis buffer (10mM Tris-HCl, pH 7.4, 5mM MgCl2, 1% Triton X-100, 100mM 
KCl, 0.02U/μL Superase-IN, 2mM DTT, and 100μg/mL cycloheximide), passed four times 
through a 26-gauge needle and cleared by centrifugation at 1,300g for 10 m at 4°C. The 
supernatant was loaded onto a 10–50% w/v linear sucrose gradient containing 20mM 
HEPES-KOH, pH 7.4, 5mM MgCl2, 100mM KCl, 2mM DTT, 100μg/mL cycloheximide, 
and 0.02U/μL Superase-IN. Gradients were centrifuged for 2 h at 36,000 rpm and 4°C and 
then fractionated by upward displacement using a Biocomp Gradient Station with 
continuous absorbance monitoring at 254 nm. Traces were quantified using Fiji. Dosing of 
replicates was performed as technical replicates from the same culture that had been split 
into three the previous day. Profiling was conducted in two separate rounds, one set of 
samples together and the other two together in consecutive weeks.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
RNAi signatures identify a spectrum of platinum drug activities. (a) A schematic 
representation of our signature-based approach. Eμ-Myc p19Arf−/− lymphoma cells are 
partially infected with GFP-tagged shRNAs targeting the indicated eight genes. The 
individual pools of eight shRNA containing cells are treated with drug to achieve 80–90% 
killing at 48 h. Relative GFP% is measured at 72 h by flow cytometry and the subsequent 
shRNA signature is compared to our reference set using our modified K-nearest neighbors 
algorithm. (b) A schematic representation of our modified K-nearest neighbors algorithm. 
First, the test compound’s nearest reference set category is identified by Euclidian K-nearest 
neighbor’s analysis. Second, the linkage ratio (L.R.) is determined by dividing the pairwise 
distances of the category containing the new drug by the category without the new drug. 
Third, the linkage ratios are then calculated for all out-of-category drugs as if they were 
members of the category in question. This generates a background distribution of negative 
control linkage ratios. Fourth, the linkage ratio of the new drug is compared to the linkage 
ratio distribution of the negative controls to obtain a p-value. If p > 0.05 then drug is 
classified as belonging to a “new class” and having a mechanism of action not represented in 
the reference set. (c) On the right, cisplatin and carboplatin, two of the three clinically 
approved platinum agents classify as DNA cross-linkers. On the left, oxaliplatin, the third 
clinically approved platinum agent, and phenanthriplatin, a mono-functional platinum agent, 
both classify as transcription/translation inhibitors. (d) A heat map showing platinum 
compound signatures, with reference compounds rapamycin, actinomycin D and 
chlorambucil included. Rapamycin and actinomycin D represent transcription/translation 
Bruno et al. Page 20
Nat Med. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
inhibitors whereas chlorambucil represents DNA cross-linkers. The other agents are shown 
classified according to their respective labels. (e) Principal components analysis of the 
platinum compounds Top2 poisons, DNA cross-linkers and transcription/translation 
inhibitors. Tables show the percent variance explained by each principal component, as well 
as the principal component 1 loadings depicting the percent contribution of each of the eight 
shRNAs for the PCA shown above. Shaded boxes represent the approximate space the 
category occupies in the PCA and are only meant to aid visualization, not category 
classification.
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Figure 2. 
Sensitivity profiles of the indicated platinum drugs on a panel of the repair-deficient DT40 
mutants. (a) Viability curves of the indicated cell lines after continuous treatment for 72 h 
with the indicated drugs. Error bars represent the S.D. (n=3). p < 0.05 (*), p < 0.01 (**) or p 
< 0.001 (***) by unpaired two-tailed Student’s t-test on the highest doses only. (b) Relative 
sensitivity of all of the DT40 mutant cell lines. A negative score and a positive score 
indicates that the cells are sensitive and resistant to the drug, respectively. The score is log2 
of the difference between IC90 (inhibitory concentration 90%) values. IC90 of wild-type cells 
are shown at the top of each panel (n=8–10). n = 3 for all others. The bars are colored 
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according to the main DNA repair function of deficient gene(s). Black; nonhomologous end 
joining (NHEJ), brown; check point, blue; homologous recombination (HR), orange: 
translesion synthesis (TLS), aqua; PARP1, green; removal of topoisomerase I or 
topoisomerase II cleavage complex, pink; Fanconi anemia (FA) pathway, light orange; DNA 
polymerase, grey; nuclease, red; nucleotide excision repair (NER), dark blue; DNA helicase.
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Figure 3. 
Phenanthriplatin and oxaliplatin exhibit distinct differences from cisplatin in cell cycle 
profiles, γ-H2AX and p53 signaling in Eμ-Myc p19arf−/− cells. (a) Results of an in vivo GFP 
competition assay. Fold change in GFP% was assessed relative to untreated mice after tumor 
cell harvesting. p < 0.01 (**) by a two-tailed Mann-Whitney test. Mean ± SEM is depicted. n 
= 5 for all conditions. (b) Cell cycle profiles of resulting from 12 h treatment by cisplatin, 
phenanthriplatin or oxaliplatin. UT: Untreated, CDDP: cisplatin, Phen: phenanthriplatin, 
Oxali: oxaliplatin (c) Western blot for γ-H2AX after cisplatin, oxaliplatin or 
phenanthriplatin treatment with or without shChk2 or shChk1 at 12 h. (d) Western blot for 
phospho-ser18 and total p53 after cisplatin, oxaliplatin or phenanthriplatin treatment with or 
without shChk2 or shChk1 at 12 h. (e) Densitometry quantification of Fig. 3c. Data are mean 
± SEM via three independent quantification results. p < 0.05 (*), p < 0.01 (**) for each group 
relative to cisplatin shChk2 or shChk1 by one-way ANOVA with Dunnett’s Multiple 
Comparison Test. (f) Densitometry quantification of Fig. 3d. Data are mean ± SEM via four 
independent quantification results. p < 0.001 (***) for each group relative to cisplatin 
shChk2 or shChk1 by one-way ANOVA with Dunnett’s Multiple Comparison Test. (g) 
Results of qPCR analysis conducted for Puma and Noxa after 4 and 12 h of cisplatin, 
phenanthriplatin or oxaliplatin treatment. Data are represented as mean ± SEM. n = 3 from 
independent experiments from independent cultures of cells.
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Figure 4. 
Immunofluorescence of γ-H2AX and comet assays reveal lack of DNA damage resulting 
from oxaliplatin and phenanthriplatin treatment in Eμ-Myc p19arf−/− cells. (a) Foci per 
nucleus for each condition at both 4 h and 8 h after treatment. Data are represented as mean 
± SEM for each field. p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***) for each group relative to 
untreated by one-way ANOVA with Dunnett’s Multiple Comparison Test. (b) Apoptotic 
cells identified via pan-nuclear γ-H2AX as a percent of total nuclei. Data are represented as 
mean ± SEM for each field. p < 0.0005 (***) for each group relative to untreated by one-way 
ANOVA with Dunnett’s Multiple Comparison Test. (c) The sum of the integrated intensity 
of pan-nuclear γ-H2AX divided by the total RFP signal for each field. Data are represented 
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as mean ± SEM for each field. p < 0.0005 (***) for each group relative to untreated by one-
way ANOVA with Dunnett’s Multiple Comparison Test. For a-c, 4 fields were analyzed for 
each condition except 4 h cisplatin and 8 h phenanthriplatin which had 5 each. (d) 
Representative images of γ-H2AX immunofluorescence staining. Insets are 2.5× magnified. 
(e) Quantification of tail moment after performing a neutral comet assay 6 h after indicated 
drug treatment. Box center line represents the mean and box limits are quartiles 1 and 3, and 
whiskers show 10th and 90th percentile. On the right, representative images from each 
untreated, cisplatin and oxaliplatin treated cells. p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***) 
for each group relative to untreated or cisplatin by one-way ANOVA with Dunnett’s 
Multiple Comparison Test. Number of comets analyzed for untreated, cisplatin, oxaliplatin, 
phenanthriplatin and actinomycin D were 117, 37, 77, 76 and 143, respectively. (f) 
Quantification of percent DNA in tail after performing a neutral comet assay 6 h after 
indicated drug treatment. Box center line represents the mean and box limits are quartiles 1 
and 3, and whiskers show 10th and 90th percentile. On right, representative images from each 
untreated, cisplatin and oxaliplatin treated cells. p < 0.05 (*) for each group relative to 
untreated or cisplatin by one-way ANOVA with Dunnett’s Multiple Comparison Test. 
Number of comets analyzed for untreated, cisplatin, oxaliplatin, phenanthriplatin and 
actinomycin D were 67, 77, 64, 50 and 91, respectively.
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Figure 5. 
Oxaliplatin and phenanthriplatin induce ribosome biogenesis stress. (a) Platinum per μg of 
nucleic acid as determined by atomic absorption spectroscopy as a result of 3 h of treatment 
of Eu-Myc p19Arf−/− lymphoma cells with cisplatin, oxaliplatin or phenanthriplatin at a 
concentration required to achieve LD80–90 at 48 h. Data are represented as mean ± SEM 
from three independent doses and cultures. p < 0.005 (**) by a two-tailed Student’s t-test. (b) 
Percent of pre-ribosomal RNA at various time points after treatment of Eu-Myc p19Arf−/− 
lymphoma cells as determined by qPCR and normalized to GAPDH. Dashed red line 
indicates no change. Data are represented as mean ± SEM from four independent doses and 
cultures except 3 h which had five. (c) A heatmap depicting enrichment or depletion of two 
validated hairpins against RPL11 as a result of drug treatment in of Eu-Myc p19Arf−/− 
lymphoma cells. (d) Above: western blot for total p53, cleaved PARP (cPARP) and GAPDH 
12 h after treatment with or without a hairpin against RPL11 in of Eu-Myc p19Arf−/− 
lymphoma cells. Below: densitometry quantification of cPARP. Shown is the ratio of cPARP 
in the shRPL11-2 condition relative to control for each treatment. Data are represented as 
mean ± SEM from three independent densitometry quantification results. (e) Representative 
polysome gradient after 6 h of treatment with the indicated agents Eμ-Myc p19arf−/− cells. 
(f) The ratio of polysomes to monosomes normalized to the untreated condition derived 
from the quantification of the area under the curve of monosome and polysome fractions. 
Data are represented as mean ± SEM from three technical dosing replicates. p < 0.01 (**) or 
p < 0.001 (***) for each group relative to cisplatin by one-way ANOVA with Dunnett’s 
Multiple Comparison Test. (g) Fraction of newly synthesized protein relative to the untreated 
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condition for Eu-Myc p19Arf−/− lymphoma cells at 9 h as measured by O-propargyl 
puromycin incorporation. Data are represented as mean ± SEM. p < 0001 (***) for each 
group relative to untreated by one-way ANOVA with Dunnett’s Multiple Comparison Test. 
All conditions were conducted with two independent doses on independent cultures. 
Number of fields analyzed was 11 for untreated, 10 for actinomycin D, oxaliplatin, cisplatin 
and carboplatin, 7 for cycloheximide and 4 for phenanthriplatin. (h) Minimum percent 
excess PI negative of Eu-Myc p19Arf−/− lymphoma cells under Bliss Independence, a control 
model of additivity, for the combination of rapamycin with either cisplatin or oxaliplatin. 
Data are represented as mean ± SEM from three independent doses on independent cultures. 
(i) Minimum percent excess PI negative cells under Bliss Independence, for the combination 
of rapamycin and oxaliplatin for which co-dosing was staggered as shown. Data are 
represented as mean ± SEM from three independent doses on independent cultures. (j) RNAi 
signatures for rapamycin or oxaliplatin, or the combination of the two dosed simultaneously 
or oxaliplatin 6 h prior to rapamycin. Both combination signatures were more similar to 
rapamycin than oxaliplatin.
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Figure 6. 
Evidence for sensitization to oxaliplatin in “translation addicted” cell lines and primary 
tumors. (a) Graphs of z-scores depicting relative resistance or sensitivity to oxaliplatin for 
various cell lines (left) or relative abundance of RSL24D1 transcript levels (right). (b) Gene 
ontology terms identified by DAVID as being significantly enriched among the 417 genes 
whose expression significantly correlated to oxaliplatin sensitivity. (c) The sole KEGG 
pathway identified by GSEA as being significantly enriched among the 417 genes whose 
expression significantly correlated to oxaliplatin sensitivity. (d) The correlation of the 
translation machinery metagene, an average of ~120 translation related gene transcripts, to 
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oxaliplatin sensitivity from the NCI-60 for lung and breast cancer cell lines. (e) A heatmap 
depicting enrichment or depletion of three validated hairpins targeting PTEN as a result of 
drug treatment of Eu-Myc p19Arf−/− lymphoma cells. (f) Left, a heatmap representing the 
relative expression of levels of all genes that are differentially expressed in ovarian cancer 
relative to colorectal cancer by an absolute fold change of at least log2(2.5). Right, the two 
non-digestion/metabolism related KEGG pathways identified by GSEA as being 
significantly enriched among the genes whose expression was greater in colorectal cancer 
relative to ovarian cancer. (g) A heatmap of expression of translation machinery genes from 
the breast cancer TCGA dataset ranked by APC expression. (h) Breast cancer cell line 
sensitivity to oxaliplatin correlates to APC expression. Each dot is labeled according to the 
name of the cell line and represents the mean of three independent replicates of both the 
dosing and qPCR from the same culture.
Bruno et al. Page 30
Nat Med. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
